Pharma News

Merck, known as MSD outside the U.S. and Canada, is set to significantly expand its workforce in India, with plans to increase employee numbers from approximately 1,800 to around 2,700 by the end of this year.

Merck has announced that it expects its leading cancer therapy, Keytruda, to be part of the government price setting initiative in 2026, with the new pricing structure set to take effect on January 1, 2028.

Eli Lilly has officially launched higher dose vials of its weight-loss drug Zepbound, priced $150 less than the existing auto-injector pen versions.

In a significant legal challenge, drug compounders have sued the U.S. Food and Drug Administration (FDA) over its recent decision to remove Wegovy and Ozempic from the official shortage list.

Gilead Sciences has announced that the European Commission (EC) has granted conditional approval for seladelpar, used in conjunction with ursodeoxycholic acid (UDCA), for the treatment of patients with primary biliary cholangitis (PBC) who do not respond

PPG Industries recently disclosed its 2024 annual report, revealing a net sales total of approximately USD 15.845 billion, marking a 2% decline from the previous year.

On February 24, BettaPharma announced the appointment of Dr. Mao Li as the new Chief R&D Officer and Chief Medical Officer. His responsibilities will include overseeing the company's new drug development and clinical research departments.

On February 24, Pfizer announced that former FDA drug chief Patrizia Cavazzoni is rejoining the company as Chief Medical Officer and Executive Vice President.

On February 20, Boehringer Ingelheim announced the appointment of Brian Hilberdink as the new President of its Human Pharma division in the United States.

On February 20, AstraZeneca announced its agreement to acquire the Chinese operations of FibroGen for approximately $160 million.

Recently, Ascletis Pharma has experienced a significant stock surge following the disclosure of promising Phase Ib clinical data for its weight loss drug ASC30.

On February 19, Hansai Aitai announced that its second phase clinical trial for HX009, in combination with the HER2-targeted antibody-drug conjugate trastuzumab deruxtecan, has been approved by China's National Medical Products Administration (NMPA).

Trump administration initiated a sweeping layoff affecting more than 2000 employees in key health agencies, including the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), and the Food and Drug Administration (FDA).

The U.S. Food and Drug Administration (FDA) is under increasing scrutiny following the recent approval of several new drugs, raising concerns regarding their safety and efficacy.

Recent findings published in the JAMA Ophthalmology have raised alarms after nine U.S. patients experienced eye complications following the use of GLP-1 receptor agonists like Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro.

Abbott Laboratories has recently announced a significant leadership change within its China diagnostics division. Fanny Chen, the long-serving president, is retiring after over 23 years with the company.

AstraZeneca has stirred discussion by asserting that its CEO's compensation should not be benchmarked against FTSE 100 companies.

The National Pharmaceutical Pricing Authority (NPPA) has mandated that pharmaceutical companies revise the Maximum Retail Price (MRP) of certain medicines following the recent customs duty exemptions announced in the Union Budget 2025.

Sanofi and Regeneron announced that the FDA has accepted the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat Bullous Pemphigoid (BP) in adults, granting it priority review status.

GSK is stepping into the spotlight with its newly approved 5-in-1 meningococcal vaccine, named Penmenvy, aimed at protecting individuals aged 10 to 25 against five major serogroups responsible for invasive meningococcal disease (IMD).